atomoxetine hydrochloride has been researched along with lisdexamfetamine dimesylate in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 7 (28.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manos, MJ | 1 |
| Kratochvil, CJ; May, DE | 1 |
| Roman, MW | 1 |
| Chae, S; Patel, A; Steinberg-Epstein, R; Wigal, SB | 1 |
| Franke, AG; Huss, M; Konrad, A; Lieb, K | 1 |
| Howland, RH | 1 |
| Bosch, R; Casas, M; Chalita, PJ; Palomar, G; Prats, L; Ramos-Quiroga, JA; Vidal, R | 1 |
| Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E | 1 |
| Connor, DF; Faraone, SV; Jensen, PS; Miesle, LM; Rostain, A | 1 |
| Anderson, CS; Bloomfield, R; Caballero, B; Cardo, E; Civil, R; Coghill, D; Dittmann, RW; Higgins, N; Hodgkins, P; Lyne, A; Nagy, P | 1 |
| Hodgkins, P; Roskell, NS; Setyawan, J; Zimovetz, EA | 1 |
| Adeyi, B; Anderson, CS; Caballero, B; Cardo, E; Civil, R; Coghill, DR; Dittmann, RW; Hodgkins, P; Nagy, P | 1 |
| Locatelli, I; Munda, B; Stuhec, M; Svab, V | 1 |
| Adeyi, B; Anderson, CS; Caballero, B; Cardo, E; Coghill, DR; Häge, A; Nagy, P; Sikirica, V | 1 |
| Barkla, XM; McArdle, PA; Newbury-Birch, D | 1 |
| Beard, SM; Bischof, M; Hodgkins, P; Mauskopf, JA; Setyawan, J; Zimovetz, EA | 1 |
| Gao, J; He, S; Li, Y; Wang, Q; Zhang, Y | 1 |
| Ayyagari, R; Joseph, A; Mauskopf, JA; Zimovetz, EA | 1 |
| Didenko, E; Maw, K; Meleshkina, D; Najib, J; Ramnarain, J; Tabassum, M; Yusupov, K | 1 |
| Bai, Z; Charach, A; Chojecki, D; Eagles, C; Elliott, J; Hossain, A; Hsieh, SC; Husereau, D; Johnston, A; Kelly, SE; Mamdani, M; Skidmore, B; Tsakonas, E; Wells, GA | 1 |
| Avillach, P; Feroe, AG; Greenspun, P; Gutiérrez-Sacristán, A; Kohane, IS; Mousavi, S; Surati, R; Uppal, N | 1 |
| Surman, CBH; Walsh, DM | 2 |
| Cesta, CE; Cohen, JM; Furu, K; Karlstad, Ø; Reutfors, J; Srinivas, C | 1 |
| Becker, SP; Froehlich, TE; Wiggs, KK | 1 |
13 review(s) available for atomoxetine hydrochloride and lisdexamfetamine dimesylate
| Article | Year |
|---|---|
Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as Topic; Dextroamphetamine; Humans; Lisdexamfetamine Dimesylate; Practice Patterns, Physicians'; Prodrugs; Propylamines; Treatment Outcome | 2008 |
Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphetamine; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines | 2010 |
[Stimulant and non-stimulant medication in current and future therapy for ADHD].
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Dextroamphetamine; Fatty Acids, Omega-3; Guanfacine; Histamine Agonists; Humans; Isoxazoles; Lisdexamfetamine Dimesylate; Memantine; Methylphenidate; Modafinil; Off-Label Use; Propylamines; Pyridines; Pyrrolidines; Receptors, AMPA | 2012 |
[Diagnosis and treatment of attention deficit hyperactivity disorder in adults].
Topics: Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Behavior Therapy; Bupropion; Central Nervous System Stimulants; Combined Modality Therapy; Comorbidity; Dextroamphetamine; Diagnostic Self Evaluation; Educational Status; Female; Humans; Interpersonal Relations; Interview, Psychological; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Neuropsychological Tests; Occupations; Propylamines; Quality of Life; Severity of Illness Index; Symptom Assessment | 2012 |
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Size; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Clonidine; Dextroamphetamine; Growth Disorders; Guanfacine; Heart Rate; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Wake Disorders; Substance-Related Disorders; Suicide Prevention; Tic Disorders; Treatment Outcome | 2013 |
Toward quality care in ADHD: defining the goals of treatment.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextroamphetamine; Goals; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines; Quality of Health Care; Treatment Outcome | 2015 |
Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphetamine; Dopamine Uptake Inhibitors; Europe; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Models, Statistical; Propylamines; Treatment Outcome | 2014 |
Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Comparative Effectiveness Research; Dextroamphetamine; Double-Blind Method; Female; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Patient Acceptance of Health Care; Propylamines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Alcohol Drinking; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextroamphetamine; Drug Interactions; Humans; Illicit Drugs; Lisdexamfetamine Dimesylate; Methylphenidate; Substance-Related Disorders | 2015 |
An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Dextroamphetamine; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Treatment Outcome | 2017 |
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bayes Theorem; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; Drug-Related Side Effects and Adverse Reactions; Female; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Modafinil; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic | 2020 |
Do Treatments for Adult ADHD Improve Emotional Behavior? A Systematic Review and Analysis.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Treatment Outcome | 2022 |
Do ADHD Treatments Improve Executive Behavior Beyond Core ADHD Symptoms in Adults? Evidence From Systematic Analysis of Clinical Trials.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Executive Function; Humans; Lisdexamfetamine Dimesylate | 2023 |
3 trial(s) available for atomoxetine hydrochloride and lisdexamfetamine dimesylate
| Article | Year |
|---|---|
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Child; Dextroamphetamine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lisdexamfetamine Dimesylate; Male; Propylamines; Treatment Outcome | 2013 |
Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Double-Blind Method; Drug Administration Schedule; Humans; Lisdexamfetamine Dimesylate; Propylamines; Remission Induction; Severity of Illness Index; Treatment Outcome | 2014 |
Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Treatment Outcome | 2016 |
9 other study(ies) available for atomoxetine hydrochloride and lisdexamfetamine dimesylate
| Article | Year |
|---|---|
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
Topics: Administration, Oral; Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Dexmethylphenidate Hydrochloride; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Half-Life; Health Care Costs; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Pediatrics; Prodrugs; Propylamines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Newly approved once-daily formulations of medications for the treatment of Attention Deficit (Hyperactivity) Disorder (ADHD) in children and adolescents.
Topics: Administration, Cutaneous; Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Dextroamphetamine; Drug Administration Schedule; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Locus Coeruleus; Methylphenidate; Neurons; Nutrition Surveys; Prefrontal Cortex; Propylamines | 2010 |
The use of dopaminergic and stimulant drugs for the treatment of depression.
Topics: Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Brain; Central Nervous System Stimulants; Depressive Disorder, Major; Dextroamphetamine; Dopamine; Dopamine Agents; Drug Therapy, Combination; Epinephrine; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Modafinil; Norepinephrine; Propylamines | 2012 |
A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cost-Benefit Analysis; Female; Health Resources; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Probability; Quality-Adjusted Life Years; Treatment Outcome | 2016 |
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cost-Benefit Analysis; Humans; Lisdexamfetamine Dimesylate; Review Literature as Topic; Treatment Outcome; United Kingdom | 2018 |
Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Lisdexamfetamine Dimesylate; Quality of Life | 2020 |
Medication Use in the Management of Comorbidities Among Individuals With Autism Spectrum Disorder From a Large Nationwide Insurance Database.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Bupropion; Child; Child, Preschool; Cohort Studies; Comorbidity; Data Mining; Depressive Disorder, Major; Dexmethylphenidate Hydrochloride; Dextroamphetamine; Female; Health Services Accessibility; Humans; Insurance; Lisdexamfetamine Dimesylate; Male; Managed Care Programs; Prevalence; Retrospective Studies | 2021 |
Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Norway; Pregnancy; Prevalence; Sweden | 2023 |
Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition; Humans; Lisdexamfetamine Dimesylate; Methylphenidate | 2023 |